Long-term survival of methotrexate in psoriatic arthritis

  • M. Ricci | office@pagepress.org
  • G. De Marco
  • F. Desiati
  • D. Mazzocchi
  • L. Rotunno
  • N. Battafarano
  • A. Marchesoni

Abstract

Objective. The purpose of this study was to evaluate the long-term survival rate of Methotrexate (MTX) in the peripheral joint involvement of psoriatic arthritis (PsA) in a setting of everyday clinical practice. Methods. This was an observational restrospective study performed using the data from a dermatological-rheumatological PsA clinic. All of the patients evaluated at this clinic from March 1997 to December 2007 who were started on MTX alone, had a three-year follow-up time or had discontinued the therapy were included into the survey. Results. Of the 174 evaluable patients, 104 (59.8%) were still taking MTX after three years of treament. The reasons of therapy discontinuation in the remaining 70 (40.2%) patients were: 34 (19.5%) lost-to-follow-up, 18 (10.3%) adverse events, 14 (8%) inefficacies, and 4 (2.3%) deaths (none related to the therapy). MTX was effective in controlling joint inflammation but not in preventing their deterioration. Overall, adverse events were recorded in 43 patients (36.4% of the 114 patients with a three-year follow-up). No serious side effect occurred in the study population. Conclusions. The results of this study showed that, in a setting of clinical pratice, MTX had a good three-year performance in patients with peripheral PsA. Almost 60% of them were still taking this drug at the end of the study period and the toxicity was more than acceptable. In our opinion, MTX might be considered the non-biological DMARD of choice for the treatment of this condition. However it should be used earlier and at higher doses.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Articles
Statistics
  • Abstract views: 779

  • PDF: 553
How to Cite
Ricci, M., De Marco, G., Desiati, F., Mazzocchi, D., Rotunno, L., Battafarano, N., & Marchesoni, A. (1). Long-term survival of methotrexate in psoriatic arthritis. Reumatismo, 61(2), 125-131. https://doi.org/10.4081/reumatismo.2009.125

Most read articles by the same author(s)